News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,441 Results
Type
Article (13612)
Company Profile (110)
Press Release (247719)
Section
Business (88007)
Career Advice (461)
Deals (15331)
Drug Delivery (64)
Drug Development (36543)
Employer Resources (49)
FDA (6263)
Job Trends (6189)
News (150121)
Policy (14024)
Tag
Academia (436)
Alliances (23103)
Alzheimer's disease (353)
Approvals (6257)
Artificial intelligence (61)
Bankruptcy (146)
Best Places to Work (4327)
Biotechnology (44)
Breast cancer (42)
Cancer (315)
Career advice (405)
Cell therapy (44)
Clinical research (30410)
Collaboration (155)
Compensation (62)
COVID-19 (748)
C-suite (52)
Data (343)
Diabetes (53)
Diagnostics (1237)
Drug pricing (57)
Earnings (31573)
Employer resources (43)
Events (36765)
Executive appointments (172)
FDA (6443)
Funding (106)
Gene therapy (59)
GLP-1 (292)
Government (1266)
Healthcare (3524)
Infectious disease (765)
Inflammatory bowel disease (46)
Interviews (58)
IPO (5817)
Job creations (2052)
Job search strategy (372)
Layoffs (167)
Legal (3420)
Lung cancer (46)
Manufacturing (99)
Medical device (1264)
Medtech (1266)
Mergers & acquisitions (9546)
Metabolic disorders (168)
Neuroscience (451)
NextGen Class of 2024 (1580)
Non-profit (594)
Northern California (433)
Obesity (101)
Opinion (109)
Patents (52)
People (28496)
Pharmaceutical (64)
Phase I (7906)
Phase II (12861)
Phase III (11554)
Pipeline (183)
Policy (45)
Postmarket research (1399)
Preclinical (3167)
Radiopharmaceuticals (116)
Rare diseases (90)
Real estate (2629)
Regulatory (9829)
Research institute (562)
Resumes & cover letters (55)
Southern California (435)
Startups (1626)
United States (4274)
Vaccines (112)
Weight loss (78)
Date
Today (42)
Last 7 days (286)
Last 30 days (1262)
Last 365 days (12714)
2024 (11613)
2023 (14250)
2022 (19576)
2021 (20084)
2020 (19055)
2019 (14903)
2018 (11721)
2017 (13901)
2016 (13136)
2015 (15487)
2014 (12425)
2013 (10608)
2012 (11396)
2011 (11923)
2010 (10894)
Location
Africa (312)
Arizona (42)
Asia (19794)
Australia (2561)
California (1006)
Canada (600)
China (111)
Colorado (41)
Connecticut (42)
Europe (38804)
Florida (151)
Illinois (111)
Indiana (86)
Japan (43)
Kansas (51)
Maryland (155)
Massachusetts (880)
Minnesota (56)
New Jersey (422)
New York (279)
North Carolina (278)
Northern California (433)
Pennsylvania (286)
South America (498)
Southern California (435)
Texas (138)
Virginia (41)
Washington State (70)
261,441 Results for "mallinckrodt pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & Acquisitions
Mallinckrodt Offloads Therakos Photopheresis Business to CVC Capital Partners for $925M
The specialty pharmaceutical company has twice filed for bankruptcy in recent years, driven by opioid-related litigation. Mallinckrodt’s deal with CVC will allow it to pay off more than half of its net debt.
August 6, 2024
·
2 min read
·
Tristan Manalac
Business
Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance
Mallinckrodt plc, a global specialty pharmaceutical company, reported its financial results for the first quarter ended March 29, 2024.
May 9, 2024
·
26 min read
Business
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
Mallinckrodt plc (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today reported its financial results for the fourth quarter and fiscal year ended December 29, 2023.
March 26, 2024
·
52 min read
Press Releases
Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance
November 5, 2024
·
38 min read
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress
Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of three posters on TERLIVAZ® for injection in patients with hepatorenal syndrome with rapid reduction in kidney function1 at the 2024 European Association for the Study of the Liver Congress taking place in Milan, Italy from June 5-8, 2024.
June 5, 2024
·
11 min read
Press Releases
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
November 18, 2024
·
9 min read
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW)
Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of two posters on TERLIVAZ® for injection in patients with hepatorenal syndrome with rapid reduction in kidney function1 at the 2024 Digestive Disease Week® taking place in Washington, DC from May 18-21, 2024.
May 18, 2024
·
9 min read
Press Releases
Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals
October 10, 2024
·
7 min read
Press Releases
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
October 30, 2024
·
11 min read
Business
Mallinckrodt Announces Appointment of Paul O’Neill as Executive Vice President, Quality & Operations, Specialty Brands
Mallinckrodt plc, a global specialty pharmaceutical company, announced that Paul O’Neill has been appointed Executive Vice President, Quality & Operations, Specialty Brands, effective immediately.
March 4, 2024
·
4 min read
1 of 26,145
Next
